Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-enabled drug discovery and will participate in the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in January 2026 [1][2] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on innovative cancer treatments, utilizing unique technologies for targeting DNA-damage response powered by AI [6] - The company has developed a pipeline of distinctive DNA-damage response inhibitors, aiming to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [7] Event Participation - Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina, will present on "Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics" at the summit [3] - In addition to his presentation, Prof. Daugaard will engage in discussions on empowering academic entrepreneurs and aligning scientific vision with investment strategy [4] Industry Context - The DDR field is experiencing significant advancements due to new discoveries in DNA damage response biology and the integration of AI into early drug discovery [5] - The summit will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, emphasizing translational strategies for clinical impact [2]